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Abstract
Background:  Depressive disorders are common, cause considerable disability, and do not always
respond to standard therapy (psychotherapy, antidepressants). Anthroposophic treatment for depression
differs from ordinary treatment in the use of artistic and physical therapies and special medication. We
studied clinical outcomes of anthroposophic therapy for depression.
Methods: 97 outpatients from 42 medical practices in Germany participated in a prospective cohort
study. Patients were aged 20–69 years and were referred to anthroposophic therapies (art, eurythmy
movement exercises, or rhythmical massage) or started physician-provided anthroposophic therapy
(counselling, medication) for depression: depressed mood, at least two of six further depressive
symptoms, minimum duration six months, Center for Epidemiological Studies Depression Scale, German
version (CES-D, range 0–60 points) of at least 24 points. Outcomes were CES-D (primary outcome) and
SF-36 after 3, 6, 12, 18, 24, and 48 months. Data were collected from July 1998 to March 2005.
Results: Median number of art/eurythmy/massage sessions was 14 (interquartile range 12–22), median
therapy duration was 137 (91–212) days. All outcomes improved significantly between baseline and all
subsequent follow-ups. Improvements from baseline to 12 months were: CES-D from mean (standard
deviation) 34.77 (8.21) to 19.55 (13.12) (p < 0.001), SF-36 Mental Component Summary from 26.11 (7.98)
to 39.15 (12.08) (p < 0.001), and SF-36 Physical Component Summary from 43.78 (9.46) to 48.79 (9.00)
(p < 0.001). All these improvements were maintained until last follow-up. At 12-month follow-up and later,
52%–56% of evaluable patients (35%–42% of all patients) were improved by at least 50% of baseline CES-
D scores. CES-D improved similarly in patients not using antidepressants or psychotherapy during the first
six study months (55% of patients).
Conclusion: In outpatients with chronic depression, anthroposophic therapies were followed by long-
term clinical improvement. Although the pre-post design of the present study does not allow for
conclusions about comparative effectiveness, study findings suggest that the anthroposophic approach,
with its recourse to non-verbal and artistic exercising therapies can be useful for patients motivated for
such therapies.
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Background
Depressive disorders are a major health problem, affecting
one-fourth to one-third of women and one-sixth of men
at some time in life [1]. Every tenth patient seen in pri-
mary care has a depressive disorder, but in half of these
patients, the depression is not diagnosed by the physician
[2].
In Europe, depressive disorders are the third leading cause
of disability [3]. Compared to the general population,
Major Depression sufferers have a 20-fold increased risk
of suicide [4]. Depressive disorders are also associated
with increased morbidity and mortality from somatic dis-
eases, including coronary heart disease [5].
Standard treatment for depression is antidepressant drugs
and/or psychotherapy. Even under the optimum condi-
tions of a clinical trial, half of included patients will not
respond to newer antidepressants [6] and up to two-thirds
of patients enrolled for psychotherapy will either not
complete treatment or not respond to it [7].
Furthermore, evidence from randomised trials of antide-
pressants (and psychotherapy) does not apply to the 86%
(and 68%) of patients with clinical features leading to
study exclusion [7,8]. Thus, for a large proportion of
depression patients, standard therapy remains unsatisfac-
tory or is not evaluated.
Anthroposophic medicine (AM) was founded in the
1920s by Rudolf Steiner and Ita Wegman [9]. AM is pro-
vided by physicians and non-medical therapists in 67
countries worldwide [10]. AM acknowledges a spiritual-
existential dimension in man which is assumed to interact
with psychological and somatic levels in health and dis-
ease. AM therapy for depression aims to counteract consti-
tutional vulnerability, stimulate salutogenetic self-healing
capacities, and strengthen patient autonomy [11].
The AM approach differs from ordinary treatment in the
use of non-verbal artistic and physical therapies [12-16]
and special AM medication [17,18], and in the existential-
ist and biographical outlook of AM-inspired counselling
and psychotherapy [19,20]. Similar to recent guideline
recommendations [21], conventional antidepressant
drugs are not used as initial therapy for mild depression.
In severe depression, however, AM therapies are often
combined with antidepressants [17].
In AM art therapy (AAT) patients engage in painting,
drawing, clay modelling, music or speech exercises [22].
In addition to psychological effects (e.g. activation, emo-
tive expression, dialogical communication with the thera-
pist and with the artistic medium [23,24]), AAT can
induce physiological effects: e.g. AAT speech exercises
have effects on heart rate rhythmicity and cardiorespira-
tory synchronisation which are not induced by spontane-
ous or controlled breathing alone [25,26].
AM eurythmy therapy (EYT, Greek "harmonious
rhythm") is an active exercise therapy, involving cogni-
tive, emotional, and volitional elements [27]. During EYT
sessions patients are instructed to perform specific move-
ments with the hands, the feet or the whole body. EYT
movements are related to the sounds of vowels and con-
sonants, to music intervals or to soul gestures, e.g. sympa-
thy-antipathy. Between therapy sessions patients practice
eurythmy movements daily [28]. EYT is assumed to have
both general effects (e.g. improving breathing patterns
and posture, strengthening muscle tone, enhancing phys-
ical vitality [11]) and specific therapeutic effects.
AM rhythmical massage therapy (RMT) was developed
from Swedish massage [13] by Ita Wegman, physician and
physiotherapist. In RMT, traditional massage techniques
(effleurage, petrissage, friction, tapotement, vibration) are
supplemented by gentle lifting and rhythmically undulat-
ing, stroking movements, where the quality of grip and
emphasis of movement are altered to promote specific
effects [11,29,30].
AM medications are of mineral, botanical or zoological
origin, and are mostly used in homeopathic dilutions
[31].
Small observational studies found positive effects from
AM therapy components in depressed inpatients
[15,16,32]. Here we present a study of comprehensive AM
therapy for depression in outpatient settings.
Methods
Study design and objective
This is a prospective four-year cohort study in a real-world
medical setting. The study was initiated by a health insur-
ance company and was part of a research project on the
effectiveness and costs of AM therapies in outpatients with
chronic disease (Anthroposophic Medicine Outcomes
Study, AMOS [33]). The primary research question was: Is
AM therapy of outpatients with depression associated
with clinically relevant improvement of depressive symp-
toms? Further research questions concerned health status,
use of adjunctive therapies, adverse reactions, and therapy
satisfaction.
Setting, participants, and therapy
Participating physicians were certified by the Physicians'
Association for Anthroposophical Medicine in Germany
and had office-based practice or worked in outpatient
clinics in Germany. Participating AM therapists were certi-
fied by the Association for Anthroposophical Art TherapyBMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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in Germany (AAT), the Eurythmy Therapy Association of
Germany (EYT), and the German Rhythmical Massage
Therapy Association (RMT), respectively.
The physicians were instructed to recruit consecutive out-
patients fulfilling the eligibility criteria. Inclusion criteria
were (1) Age 17–70 years, (2) depressed mood plus at
least two of the following symptoms (DSM-IV symptoms
of dysthymic disorder): poor appetite or overeating,
insomnia or hypersomnia, low energy or fatigue, low self-
esteem, poor concentration or difficulty making deci-
sions, feelings of hopelessness, (3) symptom duration ≥
six months, (4) Center for Epidemiological Studies
Depression Scale, German version (CES-D) of at least 24
points, (5) starting AM therapy for depressive symptoms:
referral to AM therapist (AAT, EYT or RMT) or starting AM
therapy provided by study physician (MED: AM-related
consultations, AM medication) after an initial AM-related
consultation of at least 30 min. Exclusion criteria were
previous AM therapy (AAT, EYT, RMT, or previous AM-
related consultation of at least 30 min, respectively) for
depression.
The decision to start AM therapy for depression was part
of the AM physicians' routine clinical practice. Patients
were treated according to the physicians' and therapists'
discretion. AM therapies (AAT, EYT, RMT, and MED) were
evaluated as a therapy package; other therapies, including
psychotherapy and antidepressants, were evaluated as
non-AM adjunctive therapies.
Clinical outcomes
￿ CES-D (primary outcome [34]) from 0 ("no depressive
symptoms") to 60 ("maximum symptoms"). Patients
document the frequency of 20 symptoms during the last
week, from 0 ("rarely or none of the time ≈ less than 1
day") to 3 ("most or all of the time ≈ 5–7 days"). The Ger-
man version [35] classifies persons with a score ≥ 24
points as depressed.
￿ Health status: SF-36 [36] Mental and Physical Compo-
nent Summary Measures, eight scales, and Health Change
item.
￿ Disease severity on numerical rating scales [37] from 0
(„not present“) to 10 („worst possible“): Disease Score
(physician's global assessment, documented in patients
enrolled up to 30 Sep 2000); Symptom Score (patients'
assessment of one to six most relevant symptoms present
at baseline, documented in patients enrolled after 1 Jan
1999).
Disease Score was documented after 0, 6, and 12 months,
other outcomes after 0, 3, 6, 12, 18, 24, and 48 months.
Other outcomes
￿ Therapy ratings after six and 12 months: Patient rating
of therapy outcome, patient satisfaction with therapy,
AAT/EYT/RMT effectiveness rating by patient and physi-
cian.
￿ Adverse drug or therapy reactions during the first 24
study months: cause, intensity (mild/moderate/severe =
no/some/complete impairment of normal daily activities,
respectively); Serious Adverse Events (physician and
patient documentation).
Data collection
All data were documented with questionnaires sent in
sealed envelopes to the study office. Physicians docu-
mented inclusion criteria No 2 and 3 and AM-related con-
sultations; therapists documented AAT/EYT/RMT
administration; all other items were documented by
patients, unless otherwise stated. Patient responses were
not made available to physicians. Physicians were com-
pensated €40 per included and fully documented patient,
while patients received no compensation.
Data were entered twice by two different persons into
Microsoft® Access 97. The two datasets were compared and
discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the
Faculty of Medicine Charité, Humboldt University Berlin,
and was conducted according to the Helsinki Declaration
and the ICH-GCP guidelines. Written informed consent
was obtained from all patients before enrolment.
Data analysis
The data analysis (SPSS® 13.0.1, StatXact® 5.0.3) was per-
formed on all patients fulfilling eligibility criteria. Clinical
outcomes were analysed in patients with evaluable data
for each follow-up, without replacement of missing val-
ues. For continuous data the Wilcoxon Signed-Rank test
was used for paired samples and the Mann-Whitney U-test
for independent samples, median group differences with
95% confidence interval (95%-CI) were estimated accord-
ing to Hodges and Lehmann [38]. For binominal data
McNemar test and Fisher's exact test were used. All tests
were two-tailed. Significance criteria were p < 0.05 and
95%-CI not including 0. Pre-post effect sizes were calcu-
lated as Standardised Response Mean and classified as
small (0.20–0.49), medium (0.50–0.79), and large (≥
0.80) [39].
Results
Participating physicians and therapists
59 physicians screened patients. 42 physicians included
patients into the study; these physicians did not differ sig-BMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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nificantly from all AM-certified physicians in Germany (n
= 362) regarding gender (57.1% vs. 62.2% males), age
(mean 45.9 ± 7.0 vs. 47.5 ± 7.9 years), number of years in
practice (18.8 ± 7.3 vs. 19.5 ± 8.7 years), or the proportion
of primary care physicians (90.5% vs. 85.0%). Patients
were treated by 52 AAT/EYT/RMT therapists (AAT: n = 24,
EYT: n = 23, RMT: n = 5). Comparing these therapists to
certified therapists without study patients (n = 706; AAT:
n = 230, EYT: n = 326, RMT: n = 150), no significant dif-
ferences were found regarding gender (82.7% vs. 79.3%
females), age (mean 48.4 ± 6.9 vs. 51.3 ± 9.6 years), or
median number of years since graduation from AAT
school (15.0 years, interquartile range IQR 10.0–18.0 vs.
14.0 years, IQR 11.0–19.0) or EYT school (10.0 years, IQR
7.0–14.0 vs. 12.0 years, IQR 8.0–20.0).
Patient recruitment and follow-up
From 1 July 1998 to 31 March 2001, a total of 163
patients starting AM therapy for depressive symptoms
were screened for inclusion. 97 patients fulfilled all eligi-
bility criteria and were included in the study (Figure 1).
The last patient follow-up ensued on 30 March 2005.
Included and not included patients (n = 66) did not differ
significantly regarding age, gender, duration of the depres-
sive disorder, baseline Disease Score, or baseline Symp-
tom Score. Most frequent reason for non-inclusion was
non-fulfilment of depression severity criteria (CES-D ≤ 23
points, n = 38/66); baseline CES-D score was median 34.0
(IQR 28.0–38.0) points in included and 18.0 (IQR 14.3–
23.8) points in not included patients (median difference
15.0 points, 95%-CI 12.0–18.0, p < 0.01).
The number of depression patients eligible for screening
(referred to AAT/EYT/RMT or starting MED for depressive
symptoms) during the recruitment period is not known,
but the total number of patients referred to AAT/EYT/RMT
in the AMOS project, regardless of diagnosis, was esti-
mated by the physicians (response rate 62.2%, 74/119
physicians). The proportion of referred vs. enrolled
patients was median 3.9 (IQR 0.5–10.0). There was no
correlation between this proportion and the 0–12 month
improvement of Symptom Score (Spearman-Rho -0.04, p
= 0.496, n = 364 patients).
92% (89/97) of patients were enrolled by altogether 38
primary care physicians (35 general practitioners and
three internists), 8% (8/97) were enrolled by four physi-
cians in referral practices or outpatient clinics (two
internists, two physicians with psychotherapy qualifica-
tion).
98% (95/97) of patients returned at least one follow-up
questionnaire, 2% (2/97) had no follow-up data. The 12-
month questionnaire was returned by 85% of patients;
these patients did not differ significantly from non-
respondents (15%) regarding age, gender, duration of
depressive disorder, or baseline CES-D. Corresponding
dropout analyses for 24-month follow-up also showed no
differences. The physician follow-up documentation was
available for 86% (83/97) of patients after six months and
for 85% after 12 months.
Baseline characteristics
Median duration of the depressive disorder was 5.0 (IQR
2.0–10.0) years. 80% (78/97) of patients had a current
comorbid disease, median 2.0 (IQR 1.0–3.0) diseases per
patient. Most common comorbid diseases, classified by
ICD-10, were M00-M99 Musculoskeletal Diseases
(24.6%, 46/187 diagnoses), E00–E90 Endocrine, Nutri-
tional and Metabolic Diseases (14.4%), and F00–F99
Mental Disorders (9.6%). 18% (17/97) of patients had a
current or previous comorbid mental disorder, 24% (23/
97) had a history of inpatient psychiatric treatment.
The patients were recruited from 13 of 16 German federal
states. Mean age was 42.9 ± 9.9 years (range 20–69 years).
Compared to the German population, the patients had
higher educational and occupational levels, had less daily
alcohol consumers and regular smokers, and were less
overweight; the patients' socio-demographic status was
similar to the population regarding low-income, living
alone, and sport; and less favourable for work disability
pension, severe disability status, and sick-leave (Table 1).
Therapies
At study entry, the patients started MED therapy (n = 13)
or were referred to AM therapies (n = 84, thereof AAT: n =
42, EYT: n = 36, RMT: n = 6). AAT techniques were paint-
ing/drawing/clay (n = 28), speech exercises (n = 12), and
music (n = 2). AAT/EYT/RMT was definitely administered
to 98% (82/84) of patients and started median 8 (IQR 0–
28) days after enrolment. Median therapy duration was
137 (IQR 91–212) days, median number of therapy ses-
sions was 14 (IQR 12–22, mean 16.8 ± 9.5). During the
first study year, the patients had median 1.0 (IQR 0.0–4.0,
range 0–30) AM-related consultation with their study
physician; 77% (66 of 86 evaluable patients) used AM
medication, with a median of 0.43 (IQR 0.02–1.43) AM
medications per day throughout the first study year.
In the first six study months 29% (n = 24/84) of evaluable
patients used antidepressants (ATC-Index N06A or hyper-
icum preparations) for at least six days, 24% (n = 20/84)
had at least ten psychotherapy sessions, whereas 55% (n
= 46/84) used neither psychotherapy nor antidepressants.
Clinical outcomes
CES-D, Symptom and Disease Scores, and all eleven SF-36
scores improved significantly between baseline and allBMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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Patient recruitment and follow-up Figure 1
Patient recruitment and follow-up. *18-, 24-, and 48-month follow-up questionnaires were not sent to patients enrolled 
before 1 Jan 1999.
No further questionnaires 
sent to 16 patients*
Not included: n = 66
• CES-D ≤ 23 points: n = 38
• Other depression criteria not fulfilled : n = 17
• Patients’ and physicians’ questionnaire dated 
> 30 days apart: n = 5
• No informed consent: n = 1
• Other reasons: n = 5
Included in study
n = 97
Starting AM therapy for depressive symptoms
Screened for inclusion
n = 163
6-month questionnaire 
sent to 97 patients
Returned
n = 90 (93%)
Returned
n = 90 (93%)
3-month questionnaire 
sent to 97 patients
Returned
n = 62 (77%)
24-month questionnaire 
sent to 81 patients
Returned
n = 82 (85%)
12-month questionnaire 
sent to 97 patients
Not returned
n = 7 (7%)
Not returned
n = 7 (7%)
Not returned
n = 15 (15%)
Not returned
n = 19 (23%)
Not returned
n = 16 (20%)
Returned
n = 65 (80%)
18-month questionnaire 
sent to 81 patients
Returned
n = 51 (63%)
48-month questionnaire 
sent to 81 patients
Not returned
n = 30 (37%)BMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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subsequent follow-ups. For all these 14 outcomes, the
most pronounced improvement occurred during the first
six months; improvements were maintained until the last
follow-up (Figure 2 to Figure 4). Effect sizes for the 0–12-
month comparison were large (range 0.80–1.77) for 11
outcomes and medium (0.54–0.76) for three outcomes
(Table 2). All these improvements remained stable until
the last follow-up.
CES-D improved progressively at each follow-up except
between 12 and 18 months after study entry (Figure 2). At
12-month follow-up and later, 52%–56% of evaluable
patients (35%–42% of all patients) were improved by at
least 50% of baseline CES-D scores; 66%–77% of evalua-
ble patients (47%–52% of all patients) were no longer
classified as depressed (CED-D = 23 points) (Table 3). The
CES-D improvements were similar in patients receiving
EYT and AAT, and in the AAT subgroup using painting/
drawing/clay techniques (Table 2).
In order to estimate the influence of four bias factors on
0–12 month CES-D outcomes we performed post-hoc
sensitivity analyses. The first sensitivity analysis (Table 4,
SA1) concerned dropout bias. The main analysis had
comprised all enrolled patients with evaluable CES-D data
at baseline and 12-month follow-up. In the first sensitivity
analysis, missing values after 12 months were replaced
with the last value carried forward, reducing the average
0–12 month CES-D improvement by 9% (15.23→13.90
points). The second analysis (Table 4, SA2) concerned
natural recovery, which is unlikely in depression of more
than 1–2 years duration [40-45]: The sample was
restricted to patients with a duration of the depressive dis-
order of at least 2 years, reducing the improvement by 8%
(15.23→14.05 points). The third analysis (Table 4, SA3)
concerned the effects of relevant adjunctive therapies: The
sample was restricted to patients using neither psycho-
therapy nor antidepressants in the first six study months
(see "Therapies" above). In these patients the CES-D
showed a similar improvement to that of all study
patients (15.29 vs. 15.22 points). The fourth analysis
(Table 4, SA4) concerned regression to the mean resulting
from extreme group selection due to the inclusion crite-
rion of CES-D ≥ 24: The sample was extended to also
include screened patients starting AM therapy for depres-
sive symptoms but not fulfilling all depression criteria for
study inclusion. This extension of the eligibility criteria
lead to a reduction of the average 0–12 month CES-D
improvement by 27% (analysis of patients enrolled after
1 Jan 2000: 13.38→9.82 points). Combining
Table 1: Baseline data of study population
Items Study patients German primary care patients
N% % S o u r c e
Female gender 82/97 85% 51% [57]
Age groups 20–29 years 9/97 9% 12%
30–49 years 67/97 69% 32% [57]
50–69 years 21/97 22% 23%
Duration of depressive disorder 6–11 months 10/97 10%
12–23 months 7/97 7%
≥ 24 months 80/97 82%
Study patients enrolled after 1. Jan 1999 German population
"Fachhochschule" or university entrance qualification 37/81 46% 19% [58]
University degree 13/81 16% 6% [58]
Wage earners 3/81 4% 18% [58]
Unemployed during last 12 months Economically active patients 9/70 13% 10% [58]
Living alone 16/81 20% 21% [58]
Net family income < 900 € per month 11/65 17% 16% [58]
Alcohol use daily (patients) vs. almost daily (Germany) Male 0/10 0% 28% [59]
Female 1/71 1% 11%
Regular smoking Male 2/10 20% 37% [60]
Female 11/71 15% 28%
Sports activity ≥ 1 hour weekly Age 25–69 38/79 48% 39% [61]
Body mass index < 18.5 (low) Male 0/10 0% 1% [62]
Female 5/70 7% 4%
Body mass index ≥ 25 (overweight) Male 0/10 0% 56% [62]
Female 22/70 31% 39%
Permanent work disability pension 19/81 15% 3% [63]
Severe disability status 24/81 30% 12% [64]
Sick leave days in the last 12 months (mean ± SD) Economically active patients 45 ± 82 17.0 [65]BMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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SA1+SA2+SA4, the improvement was reduced by alto-
gether 35% (13.38→8.64 points) but still remained sig-
nificant.
Other outcomes
At six-month follow-up, the patients' average therapy out-
come rating (numeric scale: 0 "no help at all", 10 "helped
very well") was 7.54 ± 1.76; patient satisfaction with ther-
apy (0 "very dissatisfied", 10 "very satisfied") was 7.92 ±
1.86. The patients' AAT/EYT/RMT effectiveness rating was
positive ("very effective" or "effective") in 88% (66/75) of
patients, and negative ("less effective", "ineffective" or
"not evaluable") in 12%. The physicians' effectiveness rat-
ing was positive in 78% (56/72) and negative in 22%. The
ratings of therapy outcome, satisfaction, and effectiveness
did not differ significantly between six- and 12-month fol-
low-ups.
During the first 24 study months adverse reactions to
AAT/EYT/RMT were reported in one patient (repeated loss
of voice after AAT singing therapy, moderate intensity),
adverse reactions to AM medication in two patients (mod-
erate dizziness from Geum urbanum – not medically con-
firmed; mild nausea from Choleodoron – medically
confirmed); none of these reactions led to therapy discon-
tinuation. Adverse reactions to non-AM medication were
reported in 12 patients (antidepressants: n = 5, other psy-
choactive drugs: n = 2, other medication: n = 5; medica-
tion stopped in three patients). One patient had adverse
reactions (pain) to psychotherapy, which was stopped.
Center for Epidemiological Studies Depression Scale (CES-D), German version Figure 2
Center for Epidemiological Studies Depression Scale (CES-D), German version. Higher scores indicate more 
depressive symptoms. Cutoff point: Subjects with a score of ≥ 24 points are classified as depressed.
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SF-36 Physical and Mental Component Summary Measures Figure 3
SF-36 Physical and Mental Component Summary Measures. Higher scores indicate better health. Adult patients and 
German population (age 17–74 years) [36].
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Disease Score (physicians' assessment), Symptom Score (patients' assessment) Figure 4
Disease Score (physicians' assessment), Symptom Score (patients' assessment). 0 "not present", 10 "worst possi-
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One Serious Adverse Event (SAE) occurred: A 53-year old
woman was acutely hospitalised because of perforation of
the small intestine after swallowing fish bones. She recov-
ered completely. This SAE had no relation to any therapy
or medication.
Discussion
This prospective cohort study is the first study of compre-
hensive AM therapy for depression, and the first depres-
sion study conducted in outpatient AM settings. The study
was conducted in conjunction with a health insurance
program and aimed to provide information on AM use
under routine conditions in Germany. We studied adult
outpatients starting AM therapies for depression
(depressed mood + at least two of six further depressive
symptoms + CES-D ≥ 24). Following AM therapies, sub-
stantial improvements of symptoms and health status
(SF-36) were observed. Improvements were maintained
during the four-year follow-up. Adverse reactions to AM
therapy or medication were infrequent (2% of patients),
of mild-to-moderate intensity, and did not require ther-
apy discontinuation.
Strengths and limitations
Strengths of this study include a long follow-up period,
high follow-up rates, and the participation of 8% of all
AM-certified physicians and AM therapists in Germany.
The participants resembled all eligible physicians/thera-
Table 3: CES-D: Responder rates at follow-ups
Follow-up 
month
CES-D improved 
from baseline
CES-D improved from 
baseline by ≥ 50%
CES-D ≤ 23 
(not depressed)
Proportion of 
evaluable patients
Proportion of all patients Proportion of evaluable 
patients
Proportion of all patients Proportion of 
evaluable patients
Proportion of all patients
N (%) N (%) N (%) N (%) N (%) N (%)
3 59/67 (88%) 59/79 (75%) 21/67 (31%) 21/79 (27%) 39/67 (58%) 39/79 (49%)
6 60/69 (87%) 60/79 (79%) 27/69 (39%) 27/79 (34%) 47/69 (68%) 47/79 (59%)
12 54/62 (87%) 54/79 (68%) 32/62 (52%) 32/79 (41%) 41/62 (66%) 41/79 (52%)
18 50/59 (85%) 50/79 (63%) 33/59 (56%) 33/79 (42%) 41/59 (69%) 41/79 (52%)
24 54/60 (90%) 54/79 (68%) 31/60 (52%) 31/79 (41%) 40/60 (67%) 40/79 (51%)
48 43/48 (90%) 43/79 (54%) 28/48 (56%) 28/79 (35%) 37/48 (77%) 37/79 (47%)
Patients enrolled after 1.1.99. CES-D: Center for Epidemiological Studies Depression Scale, German version
Table 2: Clinical outcomes 0–12 months
Item N 0 months 12 months P-value Median difference (95%-CI)* Improved** SRM
Mean (SD) Mean (SD)
CES-D (0–60)
-all patients 75 34.77 (8.21) 19.55 (13.12) p < 0.001 15.50 (12.50–18.50) 85% 1.20
-AM Art Therapy 33 36.94 (8.58) 21.12 (11.99) p < 0.001 15.50 (11.50–19.50) 91% 1.32
--painting/drawing/clay 27 38.95 (8.24) 23.18 (12.52) p < 0.001 15.00 (10.50–21.50) 91% 1.25
-Eurythmy Therapy 27 30.70 (5.55) 16.67 (13.32) p < 0.001 15.00 (8.50–19.50) 81% 1.08
Disease Score (0–10) 57 7.09 (1.38) 2.84 (2.07) p < 0.001 4.50 (4.00–5.00) 95% 1.77
Symptom Score (0–10) 69 6.35 (1.47) 3.90 (2.42) p < 0.001 2.63 (1.92–3.29) 81% 0.91
SF-36 Mental Component 80 26.11 (7.98) 39.15 (12.08) p < 0.001 13.04 (10.45–16.05) 83% 1.11
SF-36 Physical Component 80 43.78 (9.46) 48.79 (9.00) p < 0.001 4.96 (3.02–6.84) 71% 0.59
SF-36 Scales (0–100)
Physical Function 82 75.12 (22.80) 85.15 (19.00) p < 0.001 10.00 (5.00–12.50) 63% 0.54
Role Physical 81 31.58 (35.52) 68.21 (38.33) p < 0.001 50.00 (37.50–62.50) 65% 0.88
Role-Emotional 80 22.92 (32.52) 60.21 (39.38) p < 0.001 50.00 (33.34–66.67) 69% 0.87
Social Functioning 82 43.14 (22.92) 65.70 (26.48) p < 0.001 25.00 (18.75–37.50) 72% 0.80
Mental Health 81 33.48 (13.82) 56.10 (19.05) p < 0.001 22.00 (18.00–28.00) 88% 1.19
Bodily Pain 82 50.27 (26.74) 66.67 (25.06) p < 0.001 19.50 (12.50–26.00) 63% 0.65
Vitality 81 23.50 (12.47) 46.05 (19.47) p < 0.001 25.00 (20.00–30.00) 68% 1.22
General Health 81 41.80 (18.55) 55.81 (20.35) p < 0.001 13.50 (10.00–18.50) 78% 0.76
SF-36 Health Change*** 81 3.58 (1.00) 2.10 (1.08) p < 0.001 2.00 (1.50–2.00) 63% 1.06
*Positive differences indicate improvement. **Percentage of patients improved from baseline. ***SF-36 Health Change: range from 1 ("much better 
now than one year ago") to 5 ("much worse now than one year ago"). SRM: Standardised Response Mean effect size (small: 0.20–0.49, medium: 
0.50–0.79, large: ≥ 0.80)BMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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pists with respect to socio-demographic characteristics,
and included patients resembled not included, screened
patients regarding baseline characteristics. These features
suggest that the study to a high degree mirrors contempo-
rary AM practice. Nevertheless, since the study had a long
recruitment period, the participating physicians were not
able to screen all their eligible patients (patients starting
AM therapy for depressive symptoms). For the whole
AMOS project it was estimated that the physicians
enrolled every fourth patient referred to AAT/EYT/RMT.
Selection bias could be present if physicians would prefer-
entially screen and enrol such patients for whom a partic-
ularly positive outcome was expected. In this case one
would expect the degree of selection (= the proportion of
referred vs. enrolled patients) to correlate positively with
clinical outcomes. That was not the case, the correlation
was almost zero (-0.04). This analysis of AAT/EYT/RMT
patients (87% of the present cohort) does not suggest that
physicians' screening of patients starting AM therapy was
affected by selection bias.
An important limitation of the study is the absence of a
comparison group receiving another treatment or no ther-
apy. For this reason we tried as far as possible to assess the
influence of other causes apart from the AM therapies.
Sensitivity analyses were conducted in regard to regression
to the mean due to extreme group selection (CES-D ≥ 24
points at inclusion), spontaneous improvement and
dropout bias. According to the analyses, these three fac-
tors can together explain maximum 35% of the average 0–
12-month improvement. Notably, this analysis does not
completely exclude regression to the mean due to symp-
tom fluctuation with preferential self-selection to therapy
and study inclusion at symptom peaks. Another form of
self-selection bias is also possible, since a prerequisite for
study inclusion was that the patient is willing to try AM
therapy. Possibly this willingness could in itself be associ-
ated with a more favourable prognosis, which might
explain some of the observed improvement. Another con-
sequence of the prerequisite of willingness is that study
results apply only to patients who are willing to try AM
therapies.
Adjunctive treatment with antidepressants or psychother-
apy cannot explain the outcomes of our study, because
symptoms improved similarly in patients not using such
therapies. Other possible confounders are observation
bias and psychological factors. Since, however, all AM
therapies (including physician- and therapist-patient
interactions) were evaluated as a therapy package, the
question of specific therapy effects vs. non-specific effects
(placebo effects, context effects, patient expectations etc.)
was not an issue of the present analysis.
Since patients were treated by AM physicians who could
possibly have an interest in AM therapies having favoura-
ble outcomes, the study data were largely collected by
patients and not physicians. Any bias affecting physician's
documentation would not affect CES-D (primary out-
come), Symptom Score, or SF-36, since these clinical out-
comes were documented by the patients.
Included in this study were outpatients aged 17–70 years
with moderate to severe depressive symptoms. The
patients were recruited by physicians offering routine care,
and structured psychiatric interviews to assess all DSM-IV
or ICD-10 depressive disorder criteria were not feasible,
which limits diagnostic comparability with other studies.
However, all patients fulfilled the DSM-IV core symptom
criteria for dysthymic disorder and 82% of patients ful-
filled the additional criterion of at least two years symp-
tom duration.
Table 4: CES-D: Sensitivity analysis (SA) of 0–12 month outcomes
Analysis N 0 months 12 months 0–12 month difference
Mean SD Mean SD Mean SD P-value Median difference 
(95%-CI)
All patients enrolled in depression study
Main analysis: enrolled patients with evaluable data at 0 and 12 months 75 34.77 (8.21) 19.55 (13.12) 15.23 (12.72) p < 0.001 15.50 (12.50–18.50)
SA1: last value carried forward 93 34.67 (7.95) 20.77 (12.56) 13.90 (12.29) p < 0.001 15.00 (12.00–17.50)
SA2: Patients with a disease duration of ≥ 24 months 61 35.10 (8.25) 21.05 (13.53) 14.05 (13.07) p < 0.001 14.50 (10.50–17.50)
SA3 Patients not using antidepressants or psychotherapy 39 33.03 (6.98) 17.74 (12.50) 15.29 (10.80) p < 0.001 15.50 (12.00–19.00)
SA1+SA2+SA3 33 33.27 (6.88) 19.33 (13.16) 13.94 (11.85) p < 0.001 14.00 (10.00–18.00)
AMOS patients screened for depression study after 1 Jan 2000*
Main analysis: enrolled patients with evaluable data at 0 and 12 months 37 33.65 (7.64) 20.27 (13.07) 13.38 (11.98) p < 0.001 14.50 (9.50–17.50)
SA4: all screened patients (not enrolled + enrolled) with evaluable data 
at 0 and 12 months
57 28.35 (11.25) 18.53 (12.36) 9.82 (13.53) p < 0.001 10.00 (6.50–14.00)
SA1+SA2+SA4 58 29.36 (10.51) 20.72 (12.03) 8.64 (12.46) p < 0.001 9.50 (6.00–13.00)
CES-D: Center for Epidemiological Studies Depression Scale, German version. AMOS: Anthroposophic Medicine Outcomes Study. *12-month 
follow-up documentation of CES-D was not performed for AMOS patients enrolled before 1 Jan 2000, except for patients also enrolled into 
depression study. **Percentage of patients improved from baseline. SRM: Standardised Response Mean effect size (small: 0.20–0.49, medium: 0.50–
0.79, large: ≥ 0.80)BMC Psychiatry 2006, 6:57 http://www.biomedcentral.com/1471-244X/6/57
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Since AM was to be evaluated under routine conditions,
therapy was not administered according to a standardised
protocol but at the discretion of the physicians and thera-
pists. Moreover, any of four AM therapies (AAT, EYT, RMT
and MED) was permitted and the main analysis com-
prised all AM therapies. Subgroup analysis showed similar
improvement of patients receiving EYT and AAT and in
the AAT subgroup using painting/drawing/clay, but the
sample size did not allow for analysis of RMT and MED
groups nor of the other AAT technique subgroups.
Study implications
This study provides the first data on AM therapy for
depression in primary care. Notably, the female-to-male
ratio was much higher in our study (5.5/1.0) than in other
German primary care depression cohorts (1.3–2.6/1.0)
[46-50]. A high proportion of women and of patients with
higher educational levels, as observed here, has been
observed in other studies of AM users [11,51,52]. Baseline
depression severity in our study (CES-D average 35
points) was between the severity in untreated patients
with Dysthymic Disorder (34 points) and Major Depres-
sion (39 points) [35]. Baseline SF-36 Mental Component
Summary Measure (mean 26.2 ± 8.0) was slightly lower
(median difference 0.34 Standard Deviations, range 0.30–
0.72), i.e. worse, than in other primary care depression
cohorts [53-56]. Altogether, our results suggest that pri-
mary care patients receiving AM therapy for depression are
more frequently women, but resemble other depressed
primary care patients regarding symptom severity and
functional impairment. The higher proportion of women
in this sample might possibly reflect that women are more
likely than men to engage in artistic therapies like EYT and
AAT.
In the first six months after enrolment, 55% of study
patients had no standard therapy (psychotherapy, antide-
pressants) for depression. Some patients will not profit
from standard therapies; other patients discontinue stand-
ard therapies due to adverse reactions or reject them
because they are passive (antidepressants) or can be felt as
intrusive or too verbal (psychotherapy). In this context,
the AM non-verbal (AAT, EYT, RMT) and artistic exercising
therapies (AAT, EYT) offer a different approach or even a
bridge to opening up communication on a verbal level
[11].
About one-third of enrolled patients improved by at least
50% of baseline CES-D scores and remained improved
during the four-year follow-up; this rate is in the same
order of magnitude as in long-term studies of psychother-
apy for depression [7].
The results of this first study of AM therapy for depression
in outpatients are encouraging and warrant further inves-
tigations.
Conclusion
Among outpatients starting AM therapies for chronic
depression, a large proportion continued in treatment and
an encouraging proportion showed clinically relevant
improvement. Although the pre-post design of the present
study does not allow for conclusions about comparative
effectiveness, study findings suggest that AM therapies can
be useful for patients motivated for such therapies.
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